# Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer

> **NCT05721300** · NA · UNKNOWN · sponsor: **Zhongshan Hospital (Xiamen), Fudan University** · enrollment: 2215 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Chronic Hepatitis B

## Interventions

- **DRUG:** NAs（"Entecavir"or"Tenofovir"or"Tenofovir alafenamide"） combined with interferon treatments
- **DRUG:** NAs （"Entecavir"or"Tenofovir"or"Tenofovir alafenamide"） treatments

## Key facts

- **NCT ID:** NCT05721300
- **Lead sponsor:** Zhongshan Hospital (Xiamen), Fudan University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-10
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 2215 (ESTIMATED)
- **Last updated:** 2023-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05721300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05721300, "Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT05721300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*